Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes. SVB Securities is acting as sole bookrunning manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
- Axsome Therapeutics Announces Proposed Public Offering of Common Stock
- Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
- Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Biotech Alert: Searches spiking for these stocks today